PINI, Luigi Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.539
EU - Europa 10.515
AS - Asia 8.306
SA - Sud America 1.182
AF - Africa 162
Continente sconosciuto - Info sul continente non disponibili 128
OC - Oceania 16
Totale 41.848
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.141
IT - Italia 3.442
GB - Regno Unito 3.438
CN - Cina 2.554
SG - Singapore 2.337
HK - Hong Kong 942
BR - Brasile 900
VN - Vietnam 874
SE - Svezia 708
DE - Germania 550
UA - Ucraina 487
FI - Finlandia 430
FR - Francia 412
BD - Bangladesh 362
RU - Federazione Russa 287
KR - Corea 279
TR - Turchia 275
CA - Canada 229
NL - Olanda 228
BG - Bulgaria 171
IN - India 152
ID - Indonesia 129
AR - Argentina 89
IE - Irlanda 76
MX - Messico 74
JP - Giappone 51
IQ - Iraq 50
CO - Colombia 48
EC - Ecuador 48
ES - Italia 43
ZA - Sudafrica 42
AE - Emirati Arabi Uniti 38
BE - Belgio 38
PK - Pakistan 37
CL - Cile 31
CH - Svizzera 30
PL - Polonia 29
AT - Austria 28
MA - Marocco 26
VE - Venezuela 25
IR - Iran 24
PH - Filippine 21
MY - Malesia 20
CR - Costa Rica 19
BY - Bielorussia 18
TN - Tunisia 18
NP - Nepal 17
UZ - Uzbekistan 16
DZ - Algeria 15
SA - Arabia Saudita 15
EU - Europa 13
PY - Paraguay 13
IL - Israele 12
JM - Giamaica 12
LT - Lituania 12
PE - Perù 12
RO - Romania 12
SN - Senegal 12
TH - Thailandia 12
EG - Egitto 11
HN - Honduras 10
KE - Kenya 10
NI - Nicaragua 10
NO - Norvegia 10
UY - Uruguay 10
AU - Australia 9
ET - Etiopia 9
JO - Giordania 9
LB - Libano 9
GE - Georgia 8
KZ - Kazakistan 8
PT - Portogallo 8
TT - Trinidad e Tobago 8
AL - Albania 7
CZ - Repubblica Ceca 7
GT - Guatemala 7
TW - Taiwan 7
AO - Angola 6
BH - Bahrain 6
BO - Bolivia 6
DO - Repubblica Dominicana 6
GR - Grecia 6
PA - Panama 6
PR - Porto Rico 6
RS - Serbia 6
SK - Slovacchia (Repubblica Slovacca) 6
YE - Yemen 6
AZ - Azerbaigian 5
BB - Barbados 5
QA - Qatar 5
XK - ???statistics.table.value.countryCode.XK??? 5
DK - Danimarca 4
HU - Ungheria 4
NZ - Nuova Zelanda 4
PS - Palestinian Territory 4
SI - Slovenia 4
CY - Cipro 3
EE - Estonia 3
KG - Kirghizistan 3
KW - Kuwait 3
Totale 41.692
Salva come PNG Salva come JPEG
Città #
Ashburn 2.675
Southend 2.672
Santa Clara 1.786
Fairfield 1.719
Singapore 1.427
Woodbridge 1.392
Jacksonville 1.012
Houston 978
Hefei 922
Hong Kong 919
Chandler 799
San Jose 750
Wilmington 641
Dearborn 640
Seattle 610
Cambridge 573
Ann Arbor 561
Council Bluffs 548
Beijing 469
London 401
Nyköping 361
Milan 345
Los Angeles 336
Chicago 288
Ho Chi Minh City 274
Helsinki 273
Seoul 261
The Dalles 257
Hanoi 218
New York 213
Modena 201
Princeton 198
Rome 179
San Diego 176
Sofia 167
Eugene 162
Buffalo 153
Dallas 153
Lauterbourg 148
Izmir 142
São Paulo 108
Columbus 107
Moscow 105
Salt Lake City 87
Turin 83
Jakarta 78
Naples 78
Toronto 77
Bologna 75
Shanghai 72
Des Moines 71
Redwood City 69
Dublin 68
Orem 68
Phoenix 59
Atlanta 47
Brooklyn 46
Genoa 45
Palermo 45
Tokyo 45
Florence 41
Haiphong 40
Tampa 39
Verona 38
Da Nang 37
Elk Grove Village 37
Nanjing 37
Rio de Janeiro 37
Frankfurt am Main 36
Boardman 35
Brescia 35
Brussels 35
San Francisco 35
Dong Ket 33
Miami 33
Catania 32
Norwalk 32
Ottawa 32
Denver 30
Bianco 29
Chennai 29
Bremen 28
Lancaster 28
Paris 28
Philadelphia 28
Falkenstein 27
Guangzhou 27
Montreal 27
Munich 27
Falls Church 26
Mexico City 26
Miano 25
Perugia 25
Boston 24
Parma 23
Sterling 22
Tulare 22
Jinan 21
Las Vegas 21
Baghdad 20
Totale 28.639
Salva come PNG Salva come JPEG
Nome #
La flunarizina nella profilassi delel crisi emicraniche delle cefalee cclassiche e comuni 2.403
A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. 809
Effect of acetylsalicylic acid on formalin test and on serotonin system in the rat brain. 478
OPPIACEI: FARMACOCINETICA, DIPENDENZA, DETOSSIFICAZIONE, TRATTAMENTI AGONISTI ED ANTAGONISTI 454
The antinociceptive effect of acetylsalicylic acid is differently affected by a CB1 agonist or antagonist and involves the serotonergic system in rats 413
Serotonergic and opiatergic modifications induced by paracetamol as a model for daily chronic headache with analgesic overuse 391
Effect of acute and repeated administration of paracetamol on opioidergic and serotonergic systems in rats. 388
Basal cutaneous pain threshold in headache patients 388
Differential involvement of central 5-HT1B and 5-HT3 receptor subtypes in the antinociceptive effect of paracetamol 383
Serum protein changes in a rat model of chronic pain show a correlation between animal and humans 380
A genome-wide analysis in cluster headache points to neprilysin and PACAP receptor gene variants 377
Differential involvement of opioidergic and serotoninergic systems in the antinociceptive activity of N-arachidonoyl-phenolamine (AM404) in the rat: comparison with paracetamol 370
Endocannabinoids in chronic migraine: CSF findings suggest a system failure 367
Nimodipine in otolaryngology: from past evidence to clinical perspectives 354
Proteomic analysis of urine in medication-overuse headache patients: possible relation with renal damages 347
Central antinociceptive activity of acetylsalicylic acid is modulated by brain serotonin receptor subtypes 332
A case-control study of visually evoked postural responses in childhood with primary headaches 327
BRAIN-SEROTONIN BINDING-CAPACITY, ANALGESIA AND DRUG SERUM LEVELS AFTER ACUTE TREATMENT WITH PHENAZONE IN RATS 326
Validation of potential candidate biomarkers of drug-induced nephrotoxicity and allodynia in medication-overuse headache 321
Long-term follow-up of patients treated for chronic headache with analgesic overuse 319
Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis 319
Diamo parole al dolore. La percezione del disagio e della difficoltà nella vita quotidiana delle bambine e dei bambini 317
Exploration of candidate serum biomarkers potentially related to the chronic pain condition in Medication-overuse headache 317
Discovery by a proteomic approach of possible early biomarkers of drug-induced nephrotoxicity in medication-overuse headache 315
Nociceptin/orphanin FQ prevents the antinociceptive action of paracetamol on the rat hot plate test 312
A preliminary study on the relationship between central auditory processing and childhood primary headaches in the intercritical phase 311
Proteomic research of proteins involved in pain expression in an animal model of chronic pain 308
Disposition of naproxen after oral administration during and between migraine attacks. 305
NF-kappa B activity and iNOS expression in monocytes from internal jugular blood of migraine without aura patients during attacks 300
Italian guidelines for primary headaches: 2012 revised version. 300
Effect of rofecoxib on nociception and the serotonin system in the rat brain 299
Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)—a pilot study 298
Valutazione del contenuto plasmatico e possibile uso terapeutico del glutatione in pazienti con cefalea cronica quotidiana ed uso giornaliero di associazioni analgesiche 296
Serum changes of apolipoproteins in Medication Overuse Headache (MOH) 290
Acetylsalicyclic acid potentiates the antinociceptive effect of morphine in the rat:involvement of the central serotonergic system. 287
HIGH EFFICACY AND LOW-FREQUENCY OF HEADACHE RECURRENCE AFTER ORAL SUMATRIPTAN 286
O015. Evaluation of the genetic polymorphism of the α3 (CHRNA3) and α5 (CHRNA5) nicotinic receptor subunits, in patients with cluster headache 286
Genetic variation in CHRNA7 and CHRFAM7A is associated with nicotine dependence and response to varenicline treatment 285
A case of a GH-producing pituitary adenoma associated with a unilateral headache with autonomic signs 284
Anti-epileptic drugs in the preventive treatment of migraine headache : a brief review. 283
Headaches associated with chronic use of analgesics: A therapeutic approach 283
A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse 280
Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial. 278
CHRNA5 polymorphism and nicotine dependence in patients with cluster headache 274
INFLUENCE OF PROLONGED THERAPY WITH FLUNARIZINE ON GLUCOSE, INSULIN AND C-PEPTIDE METABOLISM 271
Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders 270
The potentiation of analgesic activity of paracetamol plus morphine involves the serotonergic system in rat brain 270
INTERNATIONAL-HEADACHE-SOCIETY CLASSIFICATION - INTEROBSERVER RELIABILITY IN THE DIAGNOSIS OF PRIMARY HEADACHES 269
Effects of chronic treatment with phenazone on the hot plate test and [3H]-Serotonin binding sites in pons and cortex membranes of the rat 267
Urine proteomic analysis in patients with cronic headache and overuse of analgesic drugs: possible relation with renal damage 265
Pharmacological outline of chronic headache patients: overlap between depressive and nociceptive symptomatology 264
Analgesic abuse in chronic headache sufferers 264
THE ROLE OF SEROTONIN BRAIN RECEPTORS IN THE ANALGESIC EFFECT OF PHENAZONE 264
PHYSIOLOGICAL-PARAMETERS AND PLASMA-LEVELS AFTER SHORT AND LONG-TERM PROPOFOL INFUSION 261
Lack of activity of Ketorolac in hot-plate test and serotonin binding capacity of brain membranes in rats 260
PHARMACOKINETICS OF TIAPROFENIC ACID AFTER ORAL-ADMINISTRATION IN FASTING PATIENTS DURING AND BETWEEN MIGRAINE ATTACKS 259
Evaluation of a possible relationship between medication-overuse headache and potential renal dysfunctions by a proteomic study on urine samples 258
Ambiti e limiti delle prescrizioni farmaceutiche nell'esercizio dell'odontoiatria e protesi dentaria 257
An unusual case report on the possible role of Warfarin in migraine prophylaxis 257
The effect of paracetamol and morphine combination on dynorphin A levels in the rat brain. 256
Phenytoin-Treatment Of Rdeb Vegetans 254
PHARMACOKINETIC OF REDUCED GLUTATHIONE IN MAN - EFFECT ON PLASMA CYSTEINE AND THIOL COMPOUNDS 254
The antinociceptive action of paracetamol is associated with changes in the serotonergic system in the rat brain 251
Serotonin and opiate involvement in the antinociceptive effect of acetylsalicylic acid 250
Risk-benefit and cost-benefit ratio in headache treatment 249
Tacrolimus pharmacokinetics in kidney transplant recipients. 248
Lack of association between five serotonin metabolism-relatedgenes and medication overuse headache. 248
Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension-type headache: a randomised, double-blind, double-dummy, cross-over study versus placebo and naproxen sodium 245
Influence of chronic therapy with flunarizine on glucose, insulin and C-peptide metabolism 245
Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: the results of a pilot study. 241
The effect of chronic treatment with phenazone on [3H]-serotonin binding sites in pons and cortex membranes of the rat 241
Plasma glutathione level in paracetamol daily abuser patients. Changes in plasma cysteine and thiol groups after reduced glutathione administration 241
Involvement of brain serotonergic system in the antinociceptive action of acetylsalicylic acid in the rat 236
Analysis on the use of migraine preventative drugs in current clinical practice 235
An emerging problem in clinical practice: how to treat chronic headache patients. 234
The effect of Paracetamol on nociception and dynorphin A levels in the rat brain 234
Switching from HPLC/UV to MEIA for whole blood sirolimus quantitation: Comparison of methods 234
A CB1 agonist in the treatment of medication-overuse headache: a possible therapeutic strategy 234
Plasma glutathione level in chronic headache drug abuser patients 233
Different characteristics of triptans 233
DOES CHRONIC USE OF SUMATRIPTAN INDUCE DEPENDENCE 231
Homocysteine levels and cardiovascular disease in migraine with aura 230
Chronic daily headache: how to manage it? 230
Triptans: the experience of a clinical pharmacologist in clinical practice. 229
Plasma reduced glutathione level and changes in thiol groups after glutathione administration in drug abuser patients - 228
High prevalence of patent foramen ovale in migraine with aura 226
Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels 223
Chronic treatment with phenazone modifies pontine noradrenergic receptors in rats. 223
Relevance of analgesic abuse in the maintenance of chronic headaches 222
Pharmacokinetics of tia profenic acid in headache attacks - a preliminary report 222
EFFECTS OF ACETYLSALICYCLIC ACID ON SEROTONIN BRAIN RECEPTOR SUBTYPES 222
Naloxone-reverisble antinociception by paracetamol in the rat. 221
Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study 221
Topo-kinesthetic memory in chronic headaches. A new test for chronic patients: preliminary report 221
PHARMACOKINETICS OF NAPROXEN AFTER ORAL-ADMINISTRATION DURING AND OUT OF MIGRAINE ATTACKS 219
Evaluation of the analgesic effect of nabilone versus acetaminophen plus caffeine in an inflammatory pain model (tail flik test) in rats. 219
Chronic headache and medication overuse: analysis of patients and medical interventions 218
Active reporting scheme: an example to evaluate specific adverse drug reactions. 218
Psycological profiles in tobacco and drug abusers 217
Circadian variations of proopiocortin-related peptides in children with migraine. 216
Totale 30.548
Salva come PNG Salva come JPEG
Categoria #
all - tutte 150.384
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 150.384
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.074 0 0 0 326 66 75 194 139 279 198 443 354
2022/20232.399 308 231 141 208 268 363 49 213 300 51 120 147
2023/20242.231 116 143 158 171 370 166 200 268 93 83 223 240
2024/20256.336 282 117 155 473 1.230 883 341 311 840 467 595 642
2025/202611.263 716 540 1.207 1.289 1.331 822 1.203 664 1.084 947 826 634
2026/20273.623 540 1.028 1.380 675 0 0 0 0 0 0 0 0
Totale 41.848